Search

JENKINTOWN, Pa., May 30, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the completion [...]

MARLBOROUGH, Mass., May 16, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL[sup.(TM)] RNAi platform technology is designed to make immune cells more [...]

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3761652-1&h=3201705382&u=http%3A%2F%2Fwww.vial.com%2F%3Futm_source%3Dprnewswire%26utm_medium%3Darticle%26utm_campaign%3Dhll_fpi&a=Vial, a global tech-enabled CRO providing next-generation clinical trial management services, announced that the first patient has been enrolled in the clinical trial [...]

Company Also Announces Update for Its Lead, Phase 2b Product CandidateTopical Neuromodulator ET-01 WOBURN, Mass., Oct. 17, 2022 /PRNewswire/ -- Eirion Therapeutics Inc. announced today that the first participants have [...]

STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study [...]

STOCKHOLM, Sept. 27, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company's Phase III clinical study of its drug candidate AKP02 for [...]

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, June 16, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and [...]

Company Expects to Report Initial Clinical Data in Second Half of 2021 GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 25, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in [...]

STOCKHOLM, April 22, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company's drug candidate AKP02 for [...]

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, [...]

DUBLIN, Oct. 6, 2020 /PRNewswire/ -- The 'Europe Rosacea Market and Competitive Landscape - 2020' report has been added toResearchAndMarkets.com's offering. This report provides comprehensive insights into the Rosacea pipeline, [...]

ASHDOD, Israel, Sept. 30, 2020 /PRNewswire/ --Cannassure Therapeutics Ltd (TASE: CSURE) ('Cannassure'), an Israel based developer and producer of innovative medical cannabis products, announces today the successful completion of a [...]

PITTSBURGH, Aug. 26, 2020 /PRNewswire/ -- 'I'm a doctor and I wanted to create a skincare solution to help heal a variety of problems and reduce signs of aging,' said [...]

PITTSBURGH, June 24, 2020 /PRNewswire/ -- 'I have suffered from eczema for several years and thought there could be a better way to alleviate the symptoms,' said an inventor, from [...]

PITTSBURGH, March 20, 2020 /PRNewswire/ -- An inventor from Iron Mountain, Mich., has developed the ALL IN ONE MITT, a specially designed applicator for any kind of product that must [...]

DUBLIN, June 5, 2019 /PRNewswire/ -- The 'Global Psoriasis Clinical Trial Pipeline Highlights - 2019' report has been added to ResearchAndMarkets.com's offering. Psoriasis Pipeline Highlights - 2019, provides most up-to-date [...]

Company Anticipates Reporting Topline Efficacy and Safety Results in July 2019 SAN JOSE, Calif., May 22, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on [...]

DermBiont, an early stage biopharmaceutical company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has initiated a clinical trial with its lead [...]

Company anticipates announcing topline efficacy and safety results in July 2019 SAN JOSE, Calif., March 4, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on [...]

RAMAT GAN, Israel, Jan. 30, 2019 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today reported [...]

Trial will evaluate 1% concentration of minocycline carried by company's patented HyantX(TM) delivery system MENLO PARK, Calif., Oct. 11, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical [...]

Open-label feasibility study results identify BPX-04 topical minocycline gel, 1% as optimal dose for phase 2 trial MENLO PARK, Calif., July 31, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), [...]

- Phase III clinical study designed to establish Piclidenoson is superior to placebo as primary endpoint and non-inferior to Otezla at week 32 as secondary endpoint - Global psoriasis market [...]

- 2.4 million Europeans living with moderate-to-severe psoriasis - Global psoriasis market projected to reach $13.3 billion by 2024 PETACH TIKVA, Israel, Sept. 13, 2016 /PRNewswire/ -- http://www.can-fite.com/ . (NYSE [...]

Phase III psoriasis study expected to commence in 2016 PETACH TIKVA, Israel, March 3, 2016 /PRNewswire/ -- http://www.can-fite.com/ . (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of [...]

Data expected to be released in Q1 2015 PETACH TIKVA, Israel, Feb. 4, 2015 /PRNewswire/ -- http://www.can-fite.com/ . (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary [...]

Independent, 3rd party scientists review psoriasis treatments and the benefits of small molecule drugs including CF101; The psoriasis therapeutic market was worth $3.6 billion in 2010 and is forecast to [...]

- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2) - Patients reported high satisfaction with self-administration of secukinumab pre-filled syringe or autoinjector/pen(3,4) - Secukinumab is [...]

NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA (adalimumab) [...]

MENLO PARK, California and BALLERUP, Denmark, March 18, 2013 /PRNewswire/ -- Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for [...]

Product to be launched as Absorica (TM) In the U.S. Market in Q4 2012 PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of [...]

NOVATO, Calif., Jan. 18 /PRNewswire/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY; Warrants: CLGYW) announced today it had commenced Phase III clinical trials on Glylorin(TM) for the treatment of non-bullous congenital [...]

DAYTON, N.J., June 21 /PRNewswire/ -- HYMEDIX, INC. (Nasdaq: HYMX), developers and manufacturers of medical and skin care products based on its proprietary hydrophilic polymer systems, has received Market Approval [...]

SOMERVILLE, N.J., Nov. 10 /PRNewswire/ -- The Hoechst-Roussel Pharmaceuticals Inc. Dermatology Division today announced FDA marketing approval of DermAtop(R) (prednicarbate) Emollient Cream 0.1 percent, a new midpotency topical corticosteroid. 'This [...]

IVAX, UNION CARBIDE CORPORATION ANNOUNCE FORMATION OF JOINT VENTURE TO MANUFACTURE DERMATOLOGICAL PRODUCTS MIAMI, Nov. 22 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) and Union Carbide Corporation (NYSE: UK) today announced [...]

CHANTAL PHARMACEUTICAL RECEIVES IND PERMISSION FROM FDA FOR ANTI-AGING COSMETIC PRODUCT LOS ANGELES, Sept. 20 /PRNewswire/ -- Chantal Pharmaceutical Corporation (NASDAQ: CHTL) today announced that it has received permission from [...]